一分钟看懂
这是一项关于子宫内膜癌的II 期研究，登记的药物或干预包括Abemaciclib；Letrozole；Pembrolizumab，当前状态为招募中。登记地点显示中国Boston、Foxborough、Milford、Weymouth有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Abemaciclib；Letrozole；Pembrolizumab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beth Israel Deaconess Medical Center · Boston
- Brigham and Women's Hospital · Boston
- Dana-Farber Cancer Institute · Boston
- Dana-Farber Cancer Institute at Foxborough · Foxborough
- Dana-Farber Cancer Institute at Milford · Milford
- Dana-Farber Cancer Institute at South Shore Hospital · Weymouth
公开的入选条件
- * Participants must have histologically confirmed either i) endometrioid endometrial cancer or ii) endometrial carcinosarcoma with endometrioid epithelial component.
- * Participants must have ER-positive disease, defined as ≥ 1 percent of tumor cell nuclei being immunoreactive by immunohistochemistry (IHC). If multiple analyses have been performed, judgment should be based on the most recent biopsy or pathology specimen ana
- * Tumor must be TP53 wild-type as determined by immunohistochemistry (IHC) or via CLIA-certified targeted Next-Generation Sequencing (NGS); IHC assessment of p53 status is included in the NCCN guidelines of uterine neoplasms for the molecular analysis of endom
- * Participants must have mismatch repair proficient (MMRP) endometrial cancer as determined by immunohistochemistry (IHC) or polymerase chain reaction (PCR) or any CLIA-certified next generation sequencing assay.
- * No known tumor mutational burden ≥ 10 mutations/megabase (Mb).
- * No known RB1 mutations or two-copy RB1 deletion.
- * Participants must have just completed a minimum of 4 cycles and a maximum of 10 cycles of a combination of carboplatin and taxane or a combination of taxane and anti-PD-(L)1 inhibitor therapy (e.g., pembrolizumab, or dostarlimab, or durvalumab).
- * Participants must have had measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06366347；登记信息更新于 2026-09-16。